The Catalyst

Archive

04.11.13 | By Kaelan Hollon

The third and final panel today at #PhRMA13 tried on a new definition of what we consider "disruptive", and why we should like it.  A disruptive technology or innovation improves not just what is known, but changes the modus operandi in completely unforeseen ways.

04.11.13

I’m at the PhRMA 2013 Annual Meeting in San Diego, where a panel is discussing disruptive innovation and the new challenges and opportunities it opens for the biopharmaceutical industry.

It’s a great topic. 

04.11.13 | By Kaelan Hollon

The morning panels of PhRMA's Annual Meeting provided a welcome blast of new thinking on how to create a positive geography for innovation, and further how that science gets done. As an added bonus, California Lieutenant Governor Gavin Newsom gave a super-charged address explaining how a state in grave economic flux plans to keep their leadership in bioscience.

04.11.13

Disruptive innovations in health care are often the drivers of new technologies and new treatments that enhance and build upon old modalities. The birth of osteopathic medicine in the 1870s can be seen as a “disruptive innovation” in its revolutionary approach to medical treatment.

04.11.13

John Castellani, PhRMA’s president & CEO, opened today’s afternoon session of PhRMA’s Annual Meeting in San Diego in a speech calling on policymakers, healthcare stakeholders, biopharmaceutical industry critics and sector allies alike to recognize and leverage the value of innovative medicines.

04.11.13

According to the Kaiser Family Foundation, health care expenditures in the United States approached $2.6 trillion in 2010, over ten times the $256 billion spent in 1980. 

The expectation this year: Americans will spend $2.9 trillion on health care.  And federal, state and local government agencies are in overdrive to find the best ways to reduce costs and still maintain quality patient care.  

04.11.13 | By Kaelan Hollon

There is certainly no lack of talent in the biopharmaceutical industry. Every day, employees are working hard in a variety of roles to ensure that patients get the treatments they need. It isn’t just the research scientists in the lab, it’s sales executives and communications staff who go above and beyond to advance research, progress and hope in everything they do.

04.11.13 | By John Crosby

The second #PhRMA13 panel begins at 1:45 pm EDT and will address medical breakthroughs and what needs to change to speed personalized medicine to patients. In a guest post, John Crosby, Executive Director at the American Osteopathic Association, addresses what he believes is necessary to bring science from the lab to the patient.

04.11.13 | By John Lechleiter, Ph.D.

PhRMA Chairman and Lilly President and CEO John Lechleiter is kicking off #PhRMA13 now. In a guest post he discusses the future of the industry. To learn more watch live now!

04.11.13 | By Jon Tripp

As we gear up for discussion today around research, progress and hope at our 2013 Annual Meeting in San Diego, we are enthusiastic about the re-launch of our website, PhRMA.org.

04.10.13

Today is a big day at Lilly. Not only does our CEO, John Lechleiter, begin chairing the PhRMA annual meeting, but we’re also launching a new digital communications platform that will enhance our conversations with media who cover the biopharmaceutical industry.

04.09.13

In Washington last week it was still winter.  Suddenly, with temperatures in the 80’s it is summer with a vengeance.  The caprice of weather (it is snowing in Denver today and was in the 70s over the weekend) should remind us all how we all may be vulnerable in a weather emergency – especially a hurricane, flood or

04.09.13

According to the Kaiser Family Foundation, health care expenditures in the United States approached $2.6 trillion in 2010, over ten times the $256 billion spent in 1980.

The expectation this year: Americans will spend $2.9 trillion on health care.  And federal, state and local government agencies are in overdrive to find the best ways to reduce costs and still maintain quality patient care.

04.09.13 | By Stephanie Fischer

04.09.13 | By Preet Bilinski

Recently the Partnership for Prescription Assistance (PPA) celebrated its eighth anniversary. The PPA was formed to help Americans obtain the prescription medications they need. Since its debut in April 2005, PPA has helped nearly 8 million Americans by connecting them to patient assistance programs across the country.

04.09.13 | By Preet Bilinski

Most people have heard of the NBA Hall of Famer, Kareem Abdul-Jabbar. But not everyone is as familiar with chronic myeloid leukemia (CML), a once fatal disease, that he was diagnosed with in 2008. Since being diagnosed, Abdul-Jabbar has been a strong advocate for CML patients, encouraging them to understand their treatment milestones and actively talk to their physicians to ensure their disease is properly managed.

04.08.13

According to the Kaiser Family Foundation, health care expenditures in the United States approached $2.6 trillion in 2010, over ten times the $256 billion spent in 1980. The expectation this year: Americans will spend $2.9 trillion on health care. And federal, state and local government agencies are in overdrive to find the best ways to reduce costs and still maintain quality patient care.

04.08.13

In just a few days, health care industry leaders, biomedical professionals and patients from across the country will convene at #PhRMA13 in San Diego to discuss the future of medicine and share ideas as to how we can all make PhRMA's mission of research, progress and hope an ongoing reality. The panels throughout the meeting will focus on this mission.

04.08.13 | By Mark Grayson

On April 1 the Indian Supreme Court rejected a patent for Gleevec, one of the most effective cancer therapies currently in use.

04.06.13 | By Kaelan Hollon

Have you ever considered what it took to develop medicines, like aspirin, that we use regularly? It was far from an overnight discovery. The medicines we sometimes take for granted are the result of decades of intense research and development.

Pages